<DOC>
	<DOCNO>NCT01327612</DOCNO>
	<brief_summary>The purpose protocol allow continue treatment conatumumab and/or AMG 479 , without chemotherapy subject without disease progression whose previous study close .</brief_summary>
	<brief_title>QUILT-3.030 : Open Label Extension Study Conatumumab AMG 479</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>To enrol study , subject must currently enrol prior Amgensponsored conatumumab AMG 479 study eligible accord parent study receive next dose conatumumab ( without cotherapy ) , AMG 479 alone . Subjects must eligibility assess study enrol within 30 day last treatment parent protocol Discontinued conatumumab study due adverse event consider investigator related conatumumab treatment , include intolerance conatumumab Subjects determine disease progression participation parent Amgen study Woman man partner childbearing potential consenting use adequate contraceptive precaution ie , double barrier contraceptive method ( eg , diaphragm plus condom ) , abstinence course study 6 month last dose protocolspecified therapy administration Subject pregnant breast feeding , plan become pregnant within 6 month last dose protocolspecified therapy administration Male subject pregnant partner willing use condom treatment additional 6 month last dose protocolspecified therapy administration Subject previously enter study Subject available protocol require study visit , best subject investigator 's knowledge Subject kind disorder , opinion investigator , may compromise ability subject give write informed consent and/or comply require study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AMG 655</keyword>
	<keyword>AMG 479</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Tumor Necrosis Factor</keyword>
	<keyword>Insulin-like Growth Factor</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Modified FOLFOX6</keyword>
	<keyword>mFOLFOX6</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Trail Receptor</keyword>
	<keyword>ganitumab</keyword>
	<keyword>conatumumab</keyword>
</DOC>